CRSP – CRISPR Therapeutics AG
CRISPR Therapeutics AGCRSP
$40.53Name : CRISPR Therapeutics AG
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,459,377,408.00
EPSttm : -2.79
CRISPR Therapeutics AG
$40.53
0.57%$0.23Float Short %
23.38
Margin Of Safety %
Put/Call OI Ratio
0.37
EPS Next Q Diff
-0.37
EPS Last/This Y
-3.21
EPS This/Next Y
0.14
Price
40.52
Target Price
80.65
Analyst Recom
2.1
Performance Q
-17.29
Relative Volume
0.77
Beta
1.66
Ticker: CRSP
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | CRSP | 40.38 | 0.50 | 0.49 | 92503 |
| 2024-12-20 | CRSP | 40.7 | 0.46 | 0.86 | 92546 |
| 2024-12-23 | CRSP | 40.5 | 0.50 | 0.94 | 81184 |
| 2024-12-24 | CRSP | 40.84 | 0.48 | 0.38 | 83741 |
| 2024-12-26 | CRSP | 41.08 | 0.48 | 1.24 | 84608 |
| 2024-12-27 | CRSP | 39.96 | 0.47 | 0.21 | 86107 |
| 2024-12-30 | CRSP | 38.69 | 0.48 | 0.60 | 82727 |
| 2024-12-31 | CRSP | 39.38 | 0.48 | 0.26 | 86644 |
| 2025-01-02 | CRSP | 41.42 | 0.48 | 0.14 | 89299 |
| 2025-01-03 | CRSP | 41.02 | 0.46 | 0.33 | 92955 |
| 2025-01-06 | CRSP | 42.45 | 0.47 | 0.39 | 90382 |
| 2025-01-07 | CRSP | 41.93 | 0.45 | 0.71 | 91363 |
| 2025-01-08 | CRSP | 41.27 | 0.46 | 1.07 | 92938 |
| 2025-01-09 | CRSP | 41.29 | 0.46 | 1.01 | 92938 |
| 2025-01-10 | CRSP | 39.67 | 0.45 | 0.47 | 93000 |
| 2025-01-13 | CRSP | 38.88 | 0.45 | 0.58 | 91166 |
| 2025-01-14 | CRSP | 38.35 | 0.43 | 0.24 | 93235 |
| 2025-01-15 | CRSP | 39.36 | 0.41 | 0.49 | 93032 |
| 2025-01-16 | CRSP | 40.26 | 0.40 | 0.77 | 93250 |
| 2025-01-17 | CRSP | 40.52 | 0.37 | 1.05 | 92075 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | CRSP | 40.39 | -209.6 | -48.3 | -5.15 |
| 2024-12-20 | CRSP | 40.71 | -209.6 | -67.3 | -5.15 |
| 2024-12-23 | CRSP | 40.48 | -209.6 | -56.3 | -5.15 |
| 2024-12-24 | CRSP | 40.94 | -209.6 | -69.8 | -5.15 |
| 2024-12-26 | CRSP | 41.07 | -209.6 | -63.4 | -5.15 |
| 2024-12-27 | CRSP | 40.03 | -209.6 | -41.5 | -5.15 |
| 2024-12-30 | CRSP | 38.65 | -209.6 | -33.9 | -5.15 |
| 2024-12-31 | CRSP | 39.37 | -209.6 | -76.0 | -5.15 |
| 2025-01-02 | CRSP | 41.40 | -209.6 | -102.3 | -5.15 |
| 2025-01-03 | CRSP | 41.03 | -209.6 | -53.6 | -5.15 |
| 2025-01-06 | CRSP | 42.43 | -209.6 | -87.3 | -5.15 |
| 2025-01-07 | CRSP | 41.94 | -209.6 | -52.3 | -5.15 |
| 2025-01-08 | CRSP | 41.29 | -209.6 | -49.7 | -5.15 |
| 2025-01-09 | CRSP | 41.29 | -209.6 | -60.9 | -5.15 |
| 2025-01-10 | CRSP | 39.65 | -209.6 | -30.6 | -5.15 |
| 2025-01-13 | CRSP | 38.85 | -209.6 | -44.0 | -5.15 |
| 2025-01-14 | CRSP | 38.36 | -209.6 | -50.5 | -5.15 |
| 2025-01-15 | CRSP | 39.07 | -209.6 | -76.2 | -5.15 |
| 2025-01-16 | CRSP | 40.28 | -209.6 | -86.6 | -5.15 |
| 2025-01-17 | CRSP | 40.52 | -209.6 | -65.1 | -5.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | CRSP | -1.45 | 10.00 | 22.22 |
| 2024-12-20 | CRSP | -1.45 | 10.00 | 22.22 |
| 2024-12-23 | CRSP | -1.44 | 9.89 | 22.22 |
| 2024-12-24 | CRSP | -1.44 | 9.89 | 22.22 |
| 2024-12-26 | CRSP | -1.35 | 9.89 | 22.17 |
| 2024-12-27 | CRSP | -1.36 | 9.89 | 22.17 |
| 2024-12-30 | CRSP | -1.40 | 9.90 | 22.17 |
| 2024-12-31 | CRSP | -1.40 | 9.90 | 22.17 |
| 2025-01-02 | CRSP | -1.34 | 9.90 | 22.18 |
| 2025-01-03 | CRSP | -1.35 | 9.90 | 22.18 |
| 2025-01-06 | CRSP | -1.37 | 9.90 | 22.18 |
| 2025-01-07 | CRSP | -1.37 | 9.90 | 22.18 |
| 2025-01-08 | CRSP | -1.35 | 9.90 | 22.18 |
| 2025-01-09 | CRSP | -1.35 | 9.90 | 22.18 |
| 2025-01-10 | CRSP | -1.35 | 9.90 | 22.18 |
| 2025-01-13 | CRSP | -1.35 | 9.91 | 23.38 |
| 2025-01-14 | CRSP | -1.35 | 9.91 | 23.38 |
| 2025-01-15 | CRSP | -1.35 | 9.91 | 23.38 |
| 2025-01-16 | CRSP | -1.35 | 9.91 | 23.38 |
| 2025-01-17 | CRSP | -1.35 | 9.91 | 23.38 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.01
Avg. EPS Est. Current Quarter
-1.21
Avg. EPS Est. Next Quarter
-1.38
Insider Transactions
-1.35
Institutional Transactions
9.91
Beta
1.66
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
11
Fair Value
Quality Score
33
Growth Score
35
Sentiment Score
19
Actual DrawDown %
81.6
Max Drawdown 5-Year %
-81.7
Target Price
80.65
P/E
Forward P/E
PEG
P/S
17.06
P/B
1.78
P/Free Cash Flow
EPS
-2.82
Average EPS Est. Cur. Y
-5.15
EPS Next Y. (Est.)
-5.01
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-118.13
Relative Volume
0.77
Return on Equity vs Sector %
-31.4
Return on Equity vs Industry %
-18.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
-65.1
CRISPR Therapeutics AGSector: Healthcare
Industry: Biotechnology
Employees: 407
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today
news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025
marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance
stock history CRSP – CRISPR Therapeutics AG invest stock market
stock prices CRSP premarket after hours
ticker CRSP fair value insiders trading